Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Degarelix + pTVG-AR |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Degarelix | Firmagon | FE200486 | ||
| pTVG-AR | MVI-118 | pTVG-AR (MVI-118) is a DNA vaccine encoding the ligand binding domain of the androgen receptor (AR) that stimulates immune response against AR-expressing prostate cancer cells (PMID: 23108626, PMID: 32513836). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04989946 | Phase Ib/II | Degarelix Degarelix + Nivolumab + pTVG-AR Degarelix + pTVG-AR | Androgen Deprivation, With or Without pTVG-AR, and With or Without Nivolumab, in Patients With Newly Diagnosed, High-Risk Prostate Cancer | Recruiting | USA | 0 |